Copay Assistance Programs Threatened By Medicaid Best Price Rule – PhRMA Lawsuit
The regulatory provisions being challenged are part of a Trump-era “midnight rule” that could be changed by the Biden Administration before implementation, but PhRMA is not taking any chances about the future of copay assistance programs.
You may also be interested in...
Decision is a win for the Pharmaceutical Research and Manufacturers of America in lawsuit against the US Health and Human Services Department.
Commercial payer programs to undercut manufacturer cost sharing assistance for drugs may continue next year under proposed rule released by the Centers for Medicare and Medicaid Services.
CMS final rule narrows definition of new formulations potentially subject to much higher Medicaid rebates and delays effective date of provisions targeting health plan copay accumulator programs.